Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter H O'Donnell

Showing results (1-10 of 122) with videos related to

Pageof 13
Sort By:
BJU International|March 23, 2011
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysisPeter H O'Donnell
Clinical Advances in Hematology & Oncology : H&O|October 2, 2020
Incorporating preemptive pharmacogenomic testing into the clinical settingPeter H O'Donnell
Pharmacogenomics|November 15, 2012
Bladder cancer pharmacogenomics: recent insights and future perspectivesPeter H O'Donnell
Clinical Advances in Hematology & Oncology : H&O|February 7, 2015
Unleashing the power of preemptive pharmacogenomicsPeter H O'Donnell
BJU International|June 9, 2016
Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinomaNan Sethakorn, Peter H O'Donnell
Urology|January 4, 2011
Editorial commentPeter H O'Donnell, Edwin M Posadas
CA: a Cancer Journal for Clinicians|March 18, 2022
Modern developments in germline pharmacogenomics for oncology prescribingNatalie M Reizine, Peter H O'Donnell
Advances in Urology|February 5, 2009
The role of chemotherapy in upper tract urothelial carcinomaPeter H O'Donnell, Walter M Stadler
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2012
Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?Peter H O'Donnell, Walter M Stadler
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2026
Dear Doctor: We Still Have No Idea of What Dose of Capecitabine You Should PrescribeMark J Ratain, Peter H O'Donnell
Pageof 13

Showing results (1-10 of 122) with videos related to

Sort By:
Pageof 13
BJU International|March 23, 2011
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysisPeter H O'Donnell
Clinical Advances in Hematology & Oncology : H&O|October 2, 2020
Incorporating preemptive pharmacogenomic testing into the clinical settingPeter H O'Donnell
Pharmacogenomics|November 15, 2012
Bladder cancer pharmacogenomics: recent insights and future perspectivesPeter H O'Donnell
Clinical Advances in Hematology & Oncology : H&O|February 7, 2015
Unleashing the power of preemptive pharmacogenomicsPeter H O'Donnell
BJU International|June 9, 2016
Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinomaNan Sethakorn, Peter H O'Donnell
Urology|January 4, 2011
Editorial commentPeter H O'Donnell, Edwin M Posadas
CA: a Cancer Journal for Clinicians|March 18, 2022
Modern developments in germline pharmacogenomics for oncology prescribingNatalie M Reizine, Peter H O'Donnell
Advances in Urology|February 5, 2009
The role of chemotherapy in upper tract urothelial carcinomaPeter H O'Donnell, Walter M Stadler
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2012
Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?Peter H O'Donnell, Walter M Stadler
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2026
Dear Doctor: We Still Have No Idea of What Dose of Capecitabine You Should PrescribeMark J Ratain, Peter H O'Donnell
Pageof 13